FMT is safe and well tolerated in cirrhotic patients with recurrent hepatic encephalopathy (HE) despite maximal medical therapy.
HE recurrence significantly decreased in patients receiving any FMT compared to placebo, regardless of dose, administration route (capsule or enema), or donor diet (vegan vs. omnivorous).
Higher baseline gut abundance of Lachnospiraceae and successful donor microbiota engraftment correlated with reduced HE recurrence and improved quality of life.
